TerminatedPhase 1NCT06225336

Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia (Australia)

Studying Microtia

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Auregen Biotherapeutics, SA
Principal Investigator: Joseph Dusseldorp, MD, DNP
Chris O'Brien Lifehouse
Intervention: AUR-201(combination_product)
Enrollment: 2 target
Eligibility: 8-29 years · All sexes
Timeline: 2022 – 2025

Study locations (1)

Chris O'Brien Lifehouse, Camperdown, Australia

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06225336 on ClinicalTrials.gov

Other trials for Microtia

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE2NCT06087874
Preventive Effect of Perinatal Oral Probiotic Supplementation (POPS) on Neonatal Jaundice
Chinese University of Hong Kong
ACTIVE NOT RECRUITINGNCT06289283
Microbiota in Urine and Urothelium Can be a Factor for Induction of Urinary Bladder Cancer. The Study Will Examine Urine and Bladder Cancer Tissues From Male Patients and Urine of Controls Using Whole Genomic Sequencing Techniques and 16S rRNA. The Aim is to Elucidate Role of Microbiota in Bladder
Theodor Bilharz Research Institute
RECRUITINGPHASE2NCT05288790
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
Vanderbilt University Medical Center

See all trials for Microtia →

← Back to all trials